BCRX Financial Facts

Basic and diluted net loss per common share: -0.09
Royalties: 520K
See Full Income Statement

Total stockholders' equity: 7.35M
Marketable securities: 1.9M
See Full Balance Sheet

BioCryst Pharmaceuticals, Inc. (BCRX) Earnings

  |   Expand Research on BCRX
Next EPS Date 5/8/14 *Est. EPS Growth Rate +59.1% *Last Qtr.
Average EPS % Beat Rate -9.2% Revenue Growth Rate +158.5% *Last Qtr.
Average % Move 1-Wk after EPS -3.1% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. % Since Details
2/26/14 Q413 -$0.09-$0.08 -$0.01$10.6M$8.81M N/A -33.4% Details
11/5/13 Q313 -$0.14-$0.14 $0.00$2.4M$2.01M N/A +51.1% Details
8/8/13 Q213 -$0.23-$0.14 -$0.09$821K$2.01M N/A +36.4% Details
5/7/13 Q113 -$0.09-$0.15 +$0.06$3.6M$1.31M N/A +354.8% Details
2/19/13 Q412 -$0.22-$0.16 -$0.06$4.1M$4.02M N/A +519.6% Details
11/8/12 Q312 -$0.19-$0.21 +$0.02$5.8M$4.63M = +249% Details
8/2/12 Q212 -$0.25-$0.26 +$0.01$4.2M$5.44M = +115.9% Details
5/7/12 Q112 -$0.13-$0.26 +$0.13$12.2M$5.9M = +153.7% Details